Hypothesis

Rapamycin extends lifespan by boosting autophagic flux and lysosomal biogenesis, but it does not repair the underlying defects that cause lysosomal membrane permeabilization (LMP) in aging. Overloading already‑compromised lysosomes with additional autophagic cargo could increase cathepsin leakage into the cytosol, thereby attenuating or even negating the putative longevity benefits. We hypothesize that the net effect of rapamycin on healthspan depends on the balance between induced proteolytic demand and the capacity of lysosomal membranes to resist permeabilization. When membrane‑stabilizing pathways are co‑activated, rapamycin’s autophagy upregulation should improve proteostasis without exacerbating cathepsin‑mediated damage; when they are not, rapamycin may accelerate cytosolic cathepsin activity and associated pathologies.

Mechanistic Rationale

1. Autophagy induction increases lysosomal load – Rapamycin upregulates LC3‑II conversion and autophagosome formation, delivering more long‑lived proteins and organelles to lysosomes for degradation [1]. In aged cells, lysosomal membranes are destabilized by Hsp70 carbonylation, ceramide/LysoPC accumulation, calpain activation, and v‑ATPase impairment [2].
2. Leaky lysosomes release cathepsins – Approximately one‑third of aged cortical neurons exhibit cytosolic cathepsin D due to LMP, lipofuscin buildup, and pH dysregulation [2]. Declining cystatin B further lifts inhibition on cathepsin B [3]. Brain aging also shows elevated cathepsin D, E, B but reduced cathepsin L activity [4], indicating a shift toward proteases that can trigger apoptosis or inflammasome activation when mislocalized.
3. Potential vicious cycle – Extra autophagic cargo raises intralysosomal osmotic pressure and enzymatic activity, which may exacerbate membrane stress on already‑fragile lysosomal envelopes, promoting further LMP and cathepsin efflux. This feedback could offset the clearance benefits of autophagy, especially in post‑mitotic neurons where lysosomal turnover is slow.
4. Rescue via membrane stabilization – Agents that replenish Hsp70 function (e.g., geranylgeranylacetone), inhibit ceramide synthesis (e.g., myriocin), block calpain (e.g., calpeptin), or support v‑ATPase assembly (e.g., luteolin) have been shown to reduce LMP in models of neurodegeneration [2]. Combining such stabilizers with rapamycin should allow autophagy to proceed without increasing cytosolic cathepsin load.

Testable Predictions

• Prediction 1: In aged mice, chronic rapamycin treatment alone will raise cytosolic cathepsin B/D levels in hippocampal neurons compared with untreated controls, measurable by subcellular fractionation and activity assays [3].
• Prediction 2: Co‑treatment with a lysosomal membrane stabilizer (e.g., geranylgeranylacetone) will prevent the rapamycin‑induced increase in cytosolic cathepsins while preserving or enhancing autophagic flux (LC3‑II turnover, p62 degradation).
• Prediction 3: Cognitive performance in aged mice will improve only in the combination group (rapamycin + stabilizer), not in rapamycin‑only or stabilizer‑only groups, as assessed by Morris water maze.
• Prediction 4: In primary neuronal cultures treated with rapamycin, lysosomal rupture measured by galectin‑3 puncta will be higher than in vehicle, and this increase will be abrogated by simultaneous calpain inhibition.

Experimental Approach

1. Animal study: 20‑month‑old C57BL/6 mice randomized to four groups (vehicle, rapamycin, stabilizer, rapamycin + stabilizer) for 4 months. Assess lysosomal integrity (LysoTracker loss, galectin‑3), cytosolic cathepsin activity, autophagic flux, and behavior.
2. Cellular validation: Primary cortical neurons from aged rats exposed to rapamycin (± stabilizer). Measure cathepsin release via Western blot of cytosolic fractions, autophagosome‑lysosome fusion (mCherry‑GFP‑LC3), and cell death (caspase‑3/7).
3. Rescue with genetic tools: Overexpress wild‑type Hsp70 or a cathepsin‑resistant LAMP1 mutant to test whether enhancing membrane robustness mimics the pharmacological stabilizer.

Implications

If validated, this hypothesis reframes rapamycin not as a pan‑acea but as a context‑dependent intervention whose longevity potential hinges on lysosomal membrane health. It suggests that geroprotective strategies should pair mTOR inhibition with agents that directly reinforce lysosomal integrity, thereby avoiding the pitfall of "simulating scarcity" while ignoring the structural wear that accompanies age.